The Global case-fatality rate of COVID-19 has been declining disproportionately between top vaccinated countries and the rest of the world

Author:

Haider NajmulORCID,Hasan Mohammad NayeemORCID,Khan Rumi A,McCoy DavidORCID,Ntoumi FrancineORCID,Dar OsmanORCID,Ansumana RashidORCID,Uddin Md. JamalORCID,Zumla AlimuddinORCID,Kock Richard AORCID

Abstract

AbstractGlobally 58.83% human population received at least one dose of the COVID-19 vaccines as of 5 January 2021. COVID-19 vaccination rollout is progressing at varied rates globally and data on the impact of mass vaccination on infection and case-fatality rates require definition. We compared the global reported cumulative case-fatality rate (rCFR) between top-20 countries with COVID-19 vaccination rates (>125 doses/100 people) and the rest of the world, before and after commencement of vaccination programmes.We considered the 28th day of receiving the first vaccine in the world as a cut-off to compare the pre-vaccine period (Jan 1, 2020 – Jan 5, 2021) and the post-vaccine period (Jan 6, 2021-Jan 5, 2022). We used a Generalized linear mixed model (GLMM) with a beta distribution to investigate the association between the CFR and potential predictors of each country and reported the relative risk (RR) of each variable.The mean rCFR of COVID-19 in the top-20 countries with vaccination rates was 1.83 (95% CI: 1.24-2.43) on 5 Jan 2021 and 1.18 (95% CI: 0.73-1.62) on 5 Jan 2022. The CFR for the rest of the world on 5 Jan 2021 was 2.32 (95% CI: 1.86-2.79) and 2.20 (95% CI: 1.86-2.55) on 5 January 2022. In Sub-Saharan Africa, the CFR remained roughly unchanged at 1.97 (95% CI: 1.59-2.35) on 5 Jan 2021 and 1.98 (95% CI:1.58-2.37) on 5 Jan 2022. The GLMM showed vaccination (/100 population) (RR:0.37) and Stringency Index (RR:0.88) were strong protective factors for the country’s COVID-19 CFR indicating that both vaccination and lockdown measures help in the reduction of COVID-19 CFR.The rCFR of COVID-19 continues to decline, although at a disproportionate rate between top vaccinated countries and the rest of the world. Vaccine equity and faster roll-out across the world is critically important in reducing COVID-19 transmission and CFR.Key QuestionsWhat is already knownVaccination can reduce the case-fatality rate of COVID-19. Globally, the COVID-19 vaccination rollout is progressing at varied rates.What are the new findingsIn the top-20 countries with vaccination, >200 doses of vaccines are given per 100 people on 5th Jan 2022, In the rest of the word, the figure is 105, and in Sub-Saharan Africa (SSA) only 15.72After the introduction of COVID-19 vaccination the reported case-fatality rate (rCFR) of COVID-19 has reduced by 35% in the top-20 countries with vaccination, 8% in the rest of the world roughly unchanged in SSA.The doses of COVID-19 vaccines (/100 people) and rCFR has a negative correlation on 5 Jan 2022 (r=-0.296, p<0.001).The COVID-19 vaccination and Stringency Index are strong protective factors for the country’s COVID-19 rCFR indicating that both vaccination and lockdown measures help in reduction of COVID-19 rCFR.What do the new findings implyThe disproportionate case-fatality rate of COVID-19 between top vaccinated countries and the rest of the world demand fast and equitable vaccine rollout globally to reduce COVID-19 transmission and CFR

Publisher

Cold Spring Harbor Laboratory

Reference49 articles.

1. WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva, Switzerland, 2020.

2. Estimation of novel coronavirus (COVID-19) reproduction number and case fatality rate: A systematic review and meta-analysis;Heal Sci Reports,2021

3. Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID‐19: Meta‐analysis and sensitivity analysis

4. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China;Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention;Zhonghua Liu Xing Bing Xue Za Zhi,2020

5. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis;J Infect,2020

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Regional geographies and public health lessons of the COVID-19 pandemic in the Arctic;Frontiers in Public Health;2024-01-08

2. Predictive Performance of the National Early Warning Score 2 for Stratification of Critically Ill COVID-19 Patients;Eurasian Journal of Emergency Medicine;2023-03-06

3. Hyperimmune immunoglobulin for people with COVID-19;Cochrane Database of Systematic Reviews;2023-01-26

4. Old Enemy with a New Face: Re-emerging Monkeypox Disease – An Update;Journal of Pure and Applied Microbiology;2022-12-30

5. Association between Global Monkeypox Cases and Meteorological Factors;International Journal of Environmental Research and Public Health;2022-11-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3